Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Carter

Showing results (831-840 of 872) with videos related to

Pageof 88
Sort By:
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Journal of Medicinal Chemistry|July 18, 2019
Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|January 20, 2018
Synthesis and Pharmacological Characterization of C4<sub>β</sub>-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu<sub>3</sub> Receptor AgonistJames A Monn, Steven S Henry, Steven M Massey, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
Blood|April 25, 2012
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaAnn-Kathrin Eisfeld, Guido Marcucci, Kati Maharry, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitorsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|June 17, 2016
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)John L Gilmore, James E Sheppeck, Scott H Watterson, et al.
Journal of Medicinal Chemistry|March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based SeriesScott H Watterson, Junqing Guo, Steve H Spergel, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2001
Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alphaP H Carter, P A Scherle, J K Muckelbauer, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2007
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicityJames R Pruitt, Douglas G Batt, Dean A Wacker, et al.
Pageof 88

Showing results (831-840 of 872) with videos related to

Sort By:
Pageof 88
ACS Medicinal Chemistry Letters|March 21, 2019
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid ArthritisSteven H Spergel, Michael E Mertzman, James Kempson, et al.
Journal of Medicinal Chemistry|July 18, 2019
Identification of <i>N</i>-Methyl Nicotinamide and <i>N</i>-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2)Ryan Moslin, Yanlei Zhang, Stephen T Wrobleski, et al.
Journal of Medicinal Chemistry|January 20, 2018
Synthesis and Pharmacological Characterization of C4<sub>β</sub>-Amide-Substituted 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1 S,2 S,4 S,5 R,6 S)-2-Amino-4-[(3-methoxybenzoyl)amino]bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2794193), a Highly Potent and Selective mGlu<sub>3</sub> Receptor AgonistJames A Monn, Steven S Henry, Steven M Massey, et al.
Bioorganic & Medicinal Chemistry Letters|June 14, 2023
Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variationsZili Xiao, Michael G Yang, Chunjian Liu, et al.
Blood|April 25, 2012
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaAnn-Kathrin Eisfeld, Guido Marcucci, Kati Maharry, et al.
Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitorsJames J-W Duan, Zhonghui Lu, Bin Jiang, et al.
Journal of Medicinal Chemistry|June 17, 2016
Discovery and Structure-Activity Relationship (SAR) of a Series of Ethanolamine-Based Direct-Acting Agonists of Sphingosine-1-phosphate (S1P1)John L Gilmore, James E Sheppeck, Scott H Watterson, et al.
Journal of Medicinal Chemistry|March 1, 2016
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based SeriesScott H Watterson, Junqing Guo, Steve H Spergel, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 11, 2001
Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alphaP H Carter, P A Scherle, J K Muckelbauer, et al.
Bioorganic & Medicinal Chemistry Letters|April 10, 2007
CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicityJames R Pruitt, Douglas G Batt, Dean A Wacker, et al.
Pageof 88